MorphoSys shares gain as endometrial cancer treatment gets fast-track designation
MorphoSys AG's American depositary receipts (MOR.XE) gained 2% premarket on Wednesday after the biopharma company said its investigational treatment for endometrial cancer was granted fast-track designation by the U.S. Food and Drug Administration. The treatment, tulmimetostat, is designed for patients with advanced, recurrent or metastatic endometrial cancer who have progressed on at least one prior line of treatment. The FDA's fast-track designation aims to facilitate the development and review of medicines intended to treat serious conditions and address unmet medical needs. Tulmimetostat showed promising results in an early-stage study, and MorphoSys is continuing to study the treatment across tumor types, the company said in a release. The MorphoSys ADR has gained 126% in the year to date, while the S&P 500 has gained 16%.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-13-23 0812ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
The Best REITs to Buy
-
3 Hot Stocks to Buy That Still Look Undervalued
-
After Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
Today’s Market Volatility Could Provide Tomorrow’s Opportunities
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing
-
Roblox Earnings: Weakening Engagement Has Weighed On Growth
-
The Best Gaming Stocks to Buy